From the Damian Green Lab, in collaboration with the Geoff Hill and Riddell Labs, Translational Sciences and Therapeutics Division and David Coffey, Division of Myeloma, at the University of Miami To ...

Acute Myeloid Leukemia and Myelodysplastic Syndromes After Radiation Therapy Are Similar to De Novo Disease and Differ From Other Therapy-Related Myeloid Neoplasms Patients received escalating doses ...

Researchers from DZNE, Ludwig-Maximilians-Universität München (LMU), and Technical University of Munich (TUM) have found that the enzyme "gamma-secretase"—implicated in Alzheimer's disease and ...

Model of an inhibitor targeted to g-secretase interacting with presenilin. The background shows an Alzheimer's brain that carried a presenilin mutation, with immunohistochemistry revealing abundant ...

Results presented at the National Community Oncology Dispensing Association International Spring Forum describe meaningful improvements in functioning among patients who received the oral gamma ...

Of 103 patients who received MK-0752, 21 patients received a continuous once-daily dosing at 450 and 600 mg; 17 were dosed on an intermittent schedule of 3 of 7 days at 450 and 600 mg; and 65 were ...

Springworks Therapeutics Inc.’s nirogacestat became the first drug indicated specifically for desmoid tumors, as well as the first gamma-secretase inhibitor to win marketing approval, winning a U.S.

Researchers from DZNE, Ludwig-Maximilians-Universität München (LMU), and Technical University of Munich (TUM) have found that the enzyme “gamma-secretase” – implicated in Alzheimer’s disease and ...